Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming virtual investor conferences. The first is the Wedbush PacGrow Healthcare Conference, featuring a panel discussion on August 11, 2021, at 8:35 AM ET. The second is the Canaccord Genuity Growth Conference, which includes a fireside chat on August 12, 2021, from 10:30 to 10:55 AM ET. Investors can access these sessions via the Investors & Media section of Voyager’s website. The company focuses on advancing AAV gene therapy to treat serious diseases using its TRACER™ screening platform.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -0.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.
- Wedbush PacGrow Healthcare Conference, panel discussion, August 11, 2021, 8:35 AM ET.
- Canaccord Genuity Growth Conference, fireside chat, August 12, 2021, 10:30-10:55 AM ET.
The sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurological disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Investor Inquiries:
investors@voyagertherapeutics.com
Media Inquiries:
Scott Santiamo
ssantiamo@voyagertherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.